Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (36)
Shan Yang, Tianze Zheng, Longhui Duan, Xiaoping Xue & Zhenhua Gu. (2023) Atroposelective Three‐Component Coupling of Cyclic Diaryliodoniums and Sodium Cyanate Enabled by the Dual‐Role of Phenol. Angewandte Chemie International Edition 62:21.
Crossref
Crossref
Shan Yang, Tianze Zheng, Longhui Duan, Xiaoping Xue & Zhenhua Gu. (2023) Atroposelective Three‐Component Coupling of Cyclic Diaryliodoniums and Sodium Cyanate Enabled by the Dual‐Role of Phenol. Angewandte Chemie 135:21.
Crossref
Crossref
Chih-Yu Ting, Chia-Lung Shih, Meng-Cheng Yu, Chao-Liang Wu & Sheng-Nan Wu. (2023) Characterization of Stimulatory Action on Voltage-Gated Na+ Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator. Biomedicines 11:5, pages 1351.
Crossref
Crossref
Alexander Schmidt, Jakob Balitzki, Ljubica Grmaca, Julia Vogel, Philip Boehme, Katharina Boden, Jörg Hüser, Hubert Truebel & Thomas Mondritzki. (2022) “Digital biomarkers” in preclinical heart failure models — a further step towards improved translational research. Heart Failure Reviews 28:1, pages 249-260.
Crossref
Crossref
Po-Wei Chen, Ashit Trivedi, Edward Lee, Sandeep Dutta & Malidi Ahamadi. (2022) Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction. Journal of Cardiovascular Pharmacology 79:4, pages 539-548.
Crossref
Crossref
Ashit Trivedi, Winnie Sohn, Pegah Jafarinasabian, Hanze Zhang, Bianca Terminello, Stephen Flach, Siddique Abbasi, Sandeep Dutta & Edward Lee. (2021) Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. Clinical Pharmacology in Drug Development 11:1, pages 129-133.
Crossref
Crossref
Ashit Trivedi, Rajneet K. Oberoi, Mia Mackowski, Pegah Jafarinasabian, Hanze Zhang, Stephen Flach, Shauna Hutton, Siddique Abbasi, Sandeep Dutta & Edward Lee. (2021) Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil. Clinical Pharmacology in Drug Development 10:12, pages 1442-1451.
Crossref
Crossref
Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee & Sandeep Dutta. (2021) Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model. Clinical and Translational Science 14:6, pages 2510-2520.
Crossref
Crossref
Chad S. Weldy & Euan A. Ashley. (2021) Towards precision medicine in heart failure. Nature Reviews Cardiology 18:11, pages 745-762.
Crossref
Crossref
Ashit Trivedi, Fady I. Malik, Mia Mackowski, Shauna Hutton, Makoto Aoki, Siddique Abbasi, Sandeep Dutta & Edward Lee. (2021) Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. European Journal of Drug Metabolism and Pharmacokinetics 46:6, pages 759-770.
Crossref
Crossref
Joydev K. Laha, Neha Singh & Mandeep Kaur Hunjan. (2021)
Synthesis of unsymmetrical urea from aryl- or pyridyl carboxamides and aminopyridines using PhI(OAc)
2
via in situ
formation of aryl- or pyridyl isocyanates
. New Journal of Chemistry 45:40, pages 18815-18823.
Crossref
Crossref
Ashit Trivedi, Jan Wahlstrom, Mia Mackowski, Sandeep Dutta & Edward Lee. (2021)
Pharmacokinetics, Disposition, and Biotransformation of [
14
C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose
. Drug Metabolism and Disposition 49:8, pages 619-628.
Crossref
Crossref
Ivana Sopek Merkaš, Ana Marija Slišković & Nenad Lakušić. (2021) Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. World Journal of Cardiology 13:7, pages 183-203.
Crossref
Crossref
Ashit Trivedi, Cheng‐Pang Hsu, Pegah Jafarinasabian, Bianca Terminello, Hanze Zhang, Stephen Flach, Samuel Israel, Ashley Brooks, Hongqi Xue, Borje Darpo, Siddique Abbasi, Sandeep Dutta & Edward Lee. (2021) Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations. British Journal of Clinical Pharmacology.
Crossref
Crossref
Ashit Trivedi, Rajneet K. Oberoi, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Sandeep Dutta & Edward Lee. (2021) Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. Clinical Drug Investigation 41:7, pages 647-652.
Crossref
Crossref
Manuru Mukhyaprana Prabhu, Subish Palaian & Padma Kumar. (2021) New Saviour for An Old Problem: Omecamtiv Mecarbil for Systolic Heart Failure. Journal of the Royal College of Physicians of Edinburgh 51:1, pages 43-45.
Crossref
Crossref
Neel Jayesh Shah. 2021. Introduction to Basics of Pharmacology and Toxicology. Introduction to Basics of Pharmacology and Toxicology
435
444
.
A. Pol, M. F. Hoes, R. A. Boer & P. Meer. (2020) Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine 288:5, pages 491-506.
Crossref
Crossref
Thomas F Lüscher. (2019) Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes. European Heart Journal 40:44, pages 3579-3582.
Crossref
Crossref
Manoj Manickam, Thanigaimalai Pillaiyar, Vigneshwaran Namasivayam, Pulla Reddy Boggu, Niti Sharma, Hitesh B. Jalani, Eeda Venkateswararao, You-Jung Lee, Eun-Seok Jeon, Min-Jeong Son, Sun-Hee Woo & Sang-Hun Jung. (2019) Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator. Bioorganic & Medicinal Chemistry 27:18, pages 4110-4123.
Crossref
Crossref
Olga N. Kislitsina, Jonathan D. Rich, Jane E. Wilcox, Duc T. Pham, Andrei Churyla, Esther B. Vorovich, Kambiz Ghafourian & Clyde W. Yancy. (2019) Shock – Classification and Pathophysiological Principles of Therapeutics. Current Cardiology Reviews 15:2, pages 102-113.
Crossref
Crossref
Renjie Hui, Yueying Gao, Jingyi Liu, Haili Liu, Chunlei Tang & Bainian Feng. (2019) Determination of an isonicotinylhydrazide derivative, a novel positive inotropic compound, in mouse plasma by LC–MS/MS and its application to a pharmacokinetics study. Journal of Pharmaceutical and Biomedical Analysis 165, pages 12-17.
Crossref
Crossref
Diogo Mosqueira, Ingra Mannhardt, Jamie R Bhagwan, Katarzyna Lis-Slimak, Puspita Katili, Elizabeth Scott, Mustafa Hassan, Maksymilian Prondzynski, Stephen C Harmer, Andrew Tinker, James G W Smith, Lucie Carrier, Philip M Williams, Daniel Gaffney, Thomas Eschenhagen, Arne Hansen & Chris Denning. (2018) CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. European Heart Journal 39:43, pages 3879-3892.
Crossref
Crossref
Manoj Manickam, Pulla Reddy Boggu, Thanigaimalai Pillaiyar, Niti Sharma, Hitesh B. Jalani, Eeda Venkateswararao & Sang-Hun Jung. (2018) Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator. Bioorganic & Medicinal Chemistry Letters 28:14, pages 2369-2374.
Crossref
Crossref
Péter NánásiJr.Jr., István KomáromiJános Almássy. (2018) Perspectives of a myosin motor activator agent with increased selectivity. Canadian Journal of Physiology and Pharmacology 96:7, pages 676-680.
Crossref
Crossref
Li Wang, Wenkun Dou, Manpreet Malhi, Min Zhu, Haijiao Liu, Julia Plakhotnik, Zhensong Xu, Qili Zhao, Jun Chen, Siyu Chen, Robert Hamilton, Craig A. Simmons, Jason T. Maynes & Yu Sun. (2018) Microdevice Platform for Continuous Measurement of Contractility, Beating Rate, and Beating Rhythm of Human-Induced Pluripotent Stem Cell-Cardiomyocytes inside a Controlled Incubator Environment. ACS Applied Materials & Interfaces 10:25, pages 21173-21183.
Crossref
Crossref
Manoj Manickam, Hitesh B. Jalani, Thanigaimalai Pillaiyar, Pulla Reddy Boggu, Niti Sharma, Eeda Venkateswararao, You-Jung Lee, Eun-Seok Jeon, Min-Jeong Son, Sun-Hee Woo & Sang-Hun Jung. (2018) Design and synthesis of sulfonamidophenylethylureas as novel cardiac myosin activator. European Journal of Medicinal Chemistry 143, pages 1869-1887.
Crossref
Crossref
Vincenzo B. Polsinelli, Arjun Sinha & Sanjiv J. Shah. (2017) Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Current Heart Failure Reports 14:6, pages 519-528.
Crossref
Crossref
Marco Metra & John R Teerlink. (2017) Heart failure. The Lancet 390:10106, pages 1981-1995.
Crossref
Crossref
Diana H. Kim, Feng-Ju Chien & Howard J. Eisen. (2017) Pharmacologic Management for Heart Failure and Emerging Therapies. Current Cardiology Reports 19:10.
Crossref
Crossref
Manoj Manickam, Hitesh B. Jalani, Thanigaimalai Pillaiyar, Niti Sharma, Pulla Reddy Boggu, Eeda Venkateswararao, You-Jung Lee, Eun-Seok Jeon & Sang-Hun Jung. (2017) Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure. European Journal of Medicinal Chemistry 134, pages 379-391.
Crossref
Crossref
Alexandre J.S. RibeiroOlivier SchwabMohammad A. MandegarYen-Sin AngBruce R. ConklinDeepak SrivastavaBeth L. Pruitt. (2017) Multi-Imaging Method to Assay the Contractile Mechanical Output of Micropatterned Human iPSC-Derived Cardiac Myocytes. Circulation Research 120:10, pages 1572-1583.
Crossref
Crossref
Michael K. Pugsley, Brian Guth, Alan Y. Chiang, Jennifer M. Doyle, Michael Engwall, Jean-Michel Guillon, Peter K. Hoffmann, John E. Koerner, Scott W. Mittelstadt, Jennifer Beck Pierson, Eric I. Rossman, Dustan R. Sarazan & Stanley T. Parish. (2017) An evaluation of the utility of LVdP/dt 40 , QA interval, LVdP/dt min and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs. Journal of Pharmacological and Toxicological Methods 85, pages 1-21.
Crossref
Crossref
Joseph J Cuthbert, Pierpaolo Pellicori, Parin Shah & Andrew L Clark. (2017) New pharmacological approaches in heart failure therapy: developments and possibilities. Future Cardiology 13:2, pages 173-188.
Crossref
Crossref
Silvio Weber, Stefanie Meyer-Roxlau & Ali El-Armouche. (2016) Role of protein phosphatase inhibitor-1 in cardiac beta adrenergic pathway. Journal of Molecular and Cellular Cardiology 101, pages 116-126.
Crossref
Crossref
A. Piek, R. A. de Boer & H. H. W. Sillj?. (2016) The fibrosis-cell death axis in heart failure. Heart Failure Reviews 21:2, pages 199-211.
Crossref
Crossref